Remaxol® in Patients With Drug-induced Liver Injuries During Cancer Chemotherapy

CompletedOBSERVATIONAL
Enrollment

368

Participants

Timeline

Start Date

May 12, 2022

Primary Completion Date

November 1, 2024

Study Completion Date

December 16, 2024

Conditions
CancerDrug Induced Liver Injury
Interventions
DRUG

Remaxol

Remaxol®, solution for infusions, by intravenous drop infusion in the dose of 400 ml/day, on everyday basis for 12 days

Trial Locations (5)

Unknown

State Budget-Funded Health Institution Kryzhanovsky Krasnoyarsk Krai Clinical Cancer Centre, Krasnoyarsk

North-West Center of Evidence-Based Medicine, Saint Petersburg

Pirogov Clinic of High Medical Technologies, St. Petersburg State University, Saint Petersburg

St. Petersburg State Budget-Funded Health Institution City Clinical Cancer Centre, Saint Petersburg

Republican Clinical Cancer Centre, Ufa

All Listed Sponsors
lead

POLYSAN Scientific & Technological Pharmaceutical Company

INDUSTRY